胃癌免疫治疗的研究现状及进展

doi:10.11904/j.issn.1002-3070.2023.04.012

Abstract

Abstract: Gastric cancer, as a highly invasive and heterogeneous malignant tumor, is a thorny global health issue. Currently, conventional chemotherapy for gastric cancer has limitations such as drug resistance, susceptibility to recurrence, and severe adverse reaction. In recent years, many researchers have conducted many studies in-depth on tumors related to genes and the mechanisms of tumor occurrence and development, developed kinds of new drugs for gastric cancer treatment, including targeted drugs, immunotherapy drugs, etc., and formulated different combination therapy strategies, which greatly improved the efficacy of gastric cancer patients. This article will review the research status and progress of immunotherapy for gastric cancer in recent years.

Key words: Gastric cancer, Immunotherapy, Targeted drugs

CLC Number:

R979.1

LI Juan, LIU Jiaren. The current research status and progress of immunotherapy for gastric cancer[J]. Journal of Practical Oncology, 2023, 37(4): 372-376.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.04.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I4/372

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Abbott M,Ustoyev Y.Cancer and the immune system:the history and background of immunotherapy[J].Semin Oncol Nurs,2019,35(5):150923.
3 Park R,Williamson S,Kasi A,et al.Immune therapeutics in the treatment of advanced gastric and esophageal cancer[J].Anticancer Res,2018,38(10):5569-5580.
4 Muro K,Chung HC,Shankaran V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012):a multicentre,open-label,phase 1b trial[J].Lancet Oncol,2016,17(6):717-726.
5 Fuchs CS,Doi T,Jang RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncol,2018,4(5):e180013.
6 Kang YK,Boku N,Satoh T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.
7 Boku N,Satoh T,Ryu MH,et al.Nivolumab in previously treated advanced gastric cancer(ATTRACTION-2):3-year update and outcome of treatment beyond progression with nivolumab[J].Gastric Cancer,2021,24(4):946-958.
8 Moehler M,Dvorkin M,Boku N,et al.Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers:results from javelin gastric 100[J].J Clin Oncol,2021,39(9):966-977.
9 Hosseini A,Gharibi T,Marofi F,et al.CTLA-4:From mechanism to autoimmune therapy[J].Int Immunopharmacol,2020,80:106221.
10 Ralph C,Elkord E,Burt DJ,et al.Modulation of lymphocyte regulation for cancer therapy:a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J].Clin Cancer Res,2010,16(5):1662-1672.
11 Sun JM,Shen L,Shah MA,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):a randomised,placebo-controlled,phase 3 study[J].Lancet,2021,398(10302):759-771.
12 Shitara K,Van Cutsem E,Bang YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:the KEYNOTE-062 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(10):1571-1580.
13 Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):a randomised,open-label,phase 3 trial[J].Lancet,2021,398(10294):27-40.
14 LIU T,BAI Y,LIN X,et al.First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric,gastroesophageal junction and esophageal adenocarcinoma:CheckMate 649 Chinese subgroup analysis[J].Int J Cancer,2023,152(4):749-760.
15 JIANG H,ZHENG Y,QIAN J,et al.Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial[J].BMC Cancer,2020,20(1):760.
16 XU J,JIANG H,PAN Y,et al.LBA53 Sintilimab plus chemotherapy(chemo)versus chemo as first-line treatment for advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma(ORIENT-16):First results of a randomized,double-blind,phase III study[J].Annals of Oncology,2021,32:S1331.
17 WANG F,WEI XL,WANG FH,et al.Safety,efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab,a PD-1 antibody in phase Ib/II clinical trial NCT02915432[J].Ann Oncol,2019,30(9):1479-1486.
18 Tabernero J,Bang YJ,Van Cutsem E,et al.KEYNOTE-859:a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma[J].Future Oncol,2021,17(22):2847-2855.
19 Rotte A.Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J].J Exp Clin Cancer Res,2019,38(1):255.
20 Keam S J.Cadonilimab:First Approval[J].Drugs,2022,82(12):1333-1339.
21 Janjigian YY,Bendell J,Calvo E,et al.CheckMate-032 study:efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J].J Clin Oncol,2018,36(28):2836-2844.
22 Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
23 Janjigian YY,Kawazoe A,Yaez P,et al.The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J].Nature,2021,600(7890):727-730.
24 Shitara K,Iwata H,Takahashi S,et al.Trastuzumab deruxtecan(DS-8201a)in patients with advanced HER2-positive gastric cancer:a dose-expansion,phase 1 study[J].Lancet Oncol,2019,20(6):827-836.
25 Janjigian YY,Oh D-Y,Rha SY,et al.Dose-escalation and dose-expansion study of trastuzumab deruxtecan(T-DXd)monotherapy and combinations in patients(pts)with advanced/metastatic HER2+ gastric cancer(GC)/gastroesophageal junction adenocarcinoma(GEJA):DESTINY-Gastric03[J].J Clin Oncol,2022,40(4_suppl):295.
26 Fukuoka S,Hara H,Takahashi N,et al.Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer:an open-label,dose-escalation,and dose-expansion phase Ib trial(REGONIVO,EPOC1603)[J].J Clin Oncol,2020,38(18):2053-2061.
27 Nakajima TE,Kadowaki S,Minashi K,et al.Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer[J].Clin Cancer Res,2021,27(4):1029-1036.
28 Geisler AN,Phillips GS,Barrios DM,et al.Immune checkpoint inhibitor-related dermatologic adverse events[J].J Am Acad Dermatol,2020,83(5):1255-1268.
29 CHANG X,GE X,ZHANG Y,et al.The current management and biomarkers of immunotherapy in advanced gastric cancer[J].Medicine(Baltimore),2022,101(21):e29304.
30 Alcantara M,Du Rusquec P,Romano E.Current clinical evidence and potential solutions to increase benefit of CAR T-Cell therapy for patients with solid tumors[J].Oncoimmunology,2020,9(1):1777064.
31 TAO K,HE M,TAO F,et al.Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment[J].Cancer Chemother Pharmacol,2018,82(5):815-827.
32 LV J,ZHAO R,WU D,et al.Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer[J].J Hematol Oncol,2019,12(1):18.
33 QI C,GONG J,LI J,et al.Claudin18.2-specific CAR T cells in gastrointestinal cancers:phase 1 trial interim results[J].Nat Med,2022,28(6):1189-1198.
34 HE J,XIONG X,YANG H,et al.Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response[J].Cell Res,2022,32(6):530-542.
35 Fujiwara S,Wada H,Kawada J,et al.NY-ESO-1 antibody as a novel tumour marker of gastric cancer[J].Br J Cancer,2013,108(5):1119-1125.
36 Ishikawa H,Imano M,Shiraishi O,et al.Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer[J].Gastric Cancer,2014,17(1):173-180.
37 LIU Q,CHU Y,SHAO J,et al.Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk gastric/gastroesophageal junction cancer[J].Adv Sci(Weinh),2022,10(1):e2203298.

[1]	FU Xinya, HU Lingdan, ZHANG Zhijian, MA Xiumei. HPA promotes the invasion and metastasis of human gastric cancer cells by up-regulating MCP1/CCR2 [J]. Journal of Practical Oncology, 2023, 37(4): 329-336.
[2]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.
[3]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[4]	HAN Yansong, REN Minghua. Research progression in the mechanism of bone metastasis and bone-targeted drugs in prostate cancer [J]. Journal of Practical Oncology, 2023, 37(3): 252-256.
[5]	LI Luqiao, ZOU Zhengyun. Current status of advanced research on immunotherapy for malignant melanoma [J]. Journal of Practical Oncology, 2023, 37(2): 144-148.
[6]	MING Cheng, WU Yun. Research progress of Wnt/β-catenin signaling pathway and its inhibitors in gastric cancer [J]. Journal of Practical Oncology, 2023, 37(2): 190-194.
[7]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[8]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[9]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[10]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[11]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[12]	CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions [J]. Journal of Practical Oncology, 2022, 36(6): 520-525.
[13]	XU Wei, LIU Haipeng, WANG Wenjie, WANG Zhou, LI Yuanyuan, SHEN Yimin, CHEN Xiao. Research progress on the causes and prevention measures of cholecystolithiasis after gastric cancer surgery [J]. Journal of Practical Oncology, 2022, 36(6): 561-565.
[14]	LI Hao, ZHANG Heqian, GAO Jianing, TENG Lichen. Research progress of stereotactic body radiotherapy combined with targeted drugs in metastatic renal cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 580-584.
[15]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.

The current research status and progress of immunotherapy for gastric cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments